Biosimilars Viability Debate Boils Up Between US Experts

 
• By Aidan Fry

The latest salvo has been fired in a fierce debate between US healthcare experts on whether US policymakers and payers should give up on biosimilars in favor of price controls on original biologics.

Red_Pans
A fierce debate over whether biosimilar competition can cut costs in the US is boiling up • Source: Shutterstock

More from Biosimilars

More from Products